9 results match your criteria: "Goryeb Childrens Hospital at Atlantic Health[Affiliation]"
Pediatr Dermatol
September 2019
Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Background/objectives: The development of psoriasis while on tumor necrosis factor inhibitors (TNFi) is a paradoxical effect of agents that treat psoriasis. There is a paucity of data available on this entity in juvenile idiopathic arthritis (JIA). Our objectives were to determine the prevalence of TNFi-induced psoriasis in patients with JIA at two pediatric centers, and psoriasis response to therapeutic modifications.
View Article and Find Full Text PDFJ Pediatr Gastroenterol Nutr
July 2015
*Baylor College of Medicine, Houston, TX †Wayne State University, Detroit, MI ‡Vrije Universiteit Brussels, Brussels, Belgium §Goryeb Children's Hospital at Atlantic Health, Morristown, NJ ||AstraZeneca LP, Wilmington, DE.
Objectives: To evaluate safety, tolerability, and symptom improvement with once-daily esomeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD).
Patients And Methods: In this 8-week, multicenter, randomized, uncontrolled, double-blind study, children ages 1 to 11 years were stratified by weight to receive esomeprazole 5 or 10 mg (children < 20 kg) or 10 or 20 mg (children ≥ 20 kg) once daily. Safety and tolerability was assessed by evaluating adverse events (AEs; both treatment- and non-treatment-related AEs) and changes from baseline in medical history, physical examinations, and clinical laboratory tests.
J Pediatr Orthop
January 2017
*Pediatric Orthopedic Surgery †Pediatric Endocrinology, Goryeb Children's Hospital at Atlantic Health System, Morristown, NJ ‡Hospital for Special Surgery, New York, NY.
Background: There is growing concern over the relationship between the severity of pediatric fractures and low vitamin D [25-hydroxyvitaminD (25(OH)D)] status.
Objective: Compare 25(OH)D levels and lifestyle of children with fractures to nonfracture controls to determine if 25(OH)D levels are associated with fractures and if there is a 25(OH)D fragility fracture threshold.
Methods: Pediatric fracture and nonfracture controls were included.
J Pediatr Gastroenterol Nutr
July 2015
*Baylor College of Medicine, Houston, TX †Wayne State University, Detroit, MI ‡Vrije Universiteit Brussels, Brussels, Belgium §Goryeb Children's Hospital at Atlantic Health, Morristown, NJ ||AstraZeneca LP, Wilmington, DE.
Objectives: To evaluate safety, tolerability, and symptom improvement with once-daily esomeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD).
Patients And Methods: In this 8-week, multicenter, randomized, uncontrolled, double-blind study, children ages 1 to 11 years were stratified by weight to receive esomeprazole 5 or 10 mg (children < 20 kg) or 10 or 20 mg (children ≥ 20 kg) once daily. Safety and tolerability was assessed by evaluating adverse events (AEs; both treatment- and non-treatment-related AEs) and changes from baseline in medical history, physical examinations, and clinical laboratory tests.
Curr Opin Pediatr
October 2009
Division of Pediatric Gastroenterology, Goryeb Children's Hospital at Atlantic Health, Morristown, New Jersey 07962, USA.
Purpose Of Review: Owing to its aggressive clinical course and associated immunologic abnormalities, pediatric inflammatory bowel disease (IBD) is increasingly managed with immunomodulators and biologic agents. Clinical experience with therapy targeted against tumor necrosis factor-alpha has raised important questions about these agents, which will be addressed in this review.
Recent Findings: Pediatric IBD is increasingly appreciated to have a variety of recognized clinical phenotypes that are associated with particular genotypes and serologic responses.
Curr Gastroenterol Rep
June 2008
Department of Pediatric Gastroenterology, Goryeb Children's Hospital at Atlantic Health, 100 Madison Avenue, Morristown, NJ 07962, USA.
Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn's disease unresponsive to conventional therapy. Despite significant experience with the use of this agent in children and adolescents who have inflammatory bowel disease, many questions about its optimal use remain. Recent safety concerns raised debate over the common practice of using infliximab in combination with conventional immunomodulatory agents.
View Article and Find Full Text PDFCurr Gastroenterol Rep
December 2007
Center for Pediatric Irritable Bowel and Motility Disorders, Goryeb Children's Hospital at Atlantic Health, 100 Madison Avenue, Internal Box 82, Morristown, NJ 07962, USA.
Functional dyspepsia (FD) is common in children, with as many as 80% of those being evaluated for chronic abdominal pain reporting symptoms of epigastric discomfort, nausea, or fullness. It is known that patients with persistent complaints have increased comorbidities such as depression and anxiety. The interaction with psychopathologic variables has been found to mediate the association between upper abdominal pain and gastric hypersensitivity.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
March 2008
Center for Pediatric Irritable Bowel & Motility Disorders, Goryeb Childrens Hospital at Atlantic Health, Morristown, New Jersey, USA.
Background & Aims: Abdominal pain is common in adolescence. The aim of this study was to determine the prevalence of depressive symptoms in a large cohort of patients with frequent abdominal pain.
Methods: A prospective, cross-sectional, nationally representative sample of children aged 13 to 18 years (mean age, 16.
Curr Treat Options Gastroenterol
October 2007
Nader N. Youssef, Center for Pediatric Irritable Bowel and Motility Disorders, Goryeb Children’s Hospital at Atlantic Health, University of Medicine and Dentistry of New Jersey, 100 Madison Avenue, Internal Box 82, Morristown, NJ 07962, USA.
Constipation is a common symptom throughout all ages in the pediatric population, both sexes, and all educational and socioeconomic levels. It is estimated that 12% to 30% of the general population suffers from functional constipation. A practical overview of pathogenic mechanisms contributing to constipation is presented, with emphasis on evaluation and management options available to the treating practitioner.
View Article and Find Full Text PDF